These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32681007)

  • 21. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
    Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
    Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
    Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD
    J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
    Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A sodium alginate intervention strategy to enhance therapeutic effects of bone-targeted alpha therapy via remodeling
    Xue S; Li D; Zhou P; Lu X; Bai Q; Zhang L; Liu X; Lou J; Li X; Wang R
    Int J Biol Macromol; 2024 Mar; 260(Pt 1):129364. PubMed ID: 38219927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
    Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
    Nilsson S
    Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
    Dizdarevic S; McCready R; Vinjamuri S
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):192-217. PubMed ID: 31471713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
    Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nano-hydroxyapatite radiolabeled with radium dichloride [
    Gemini-Piperni S; Ricci-Junior E; İlem-Özdemir D; da Silva Batista B; Alencar LMR; Rossi AM; Santos-Oliveira R
    Colloids Surf B Biointerfaces; 2023 Mar; 223():113174. PubMed ID: 36746067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compartmental Model for
    Taprogge J; Murray I; Gear J; Chittenden SJ; Parker CC; Flux GD
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):884-892. PubMed ID: 31349058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H; König F; Klutmann S
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.